Aussie clinical stage biotech company Cynata Therapeutics (ASX: CYP) has marked a milestone in its Phase 2 clinical trial of CYP-001 for high-risk acute graft versus host disease (aGvHD) with the enrolment and treatment of its first patient. High-risk acute graft versus host disease (aGvHD) is a serious complication that can occur after a stem
Read More
If you key in the word “stem cell” into a search engine, results will show they have the potential to treat most diseases (but don’t forget to look for clinically-proven sources!) There also exists an ASX-listed company focusing in stem cell therapeutics, aiming to be the panacea in treating the High-Risk acute Graft versus Host
Read More
The first successful organ donation occurred in 1954 where a living donor gave a kidney to his identical twin. Since then, organ donation has become a routine practice with over 25,000 transplants conducted per year in US hospitals. Transplantation is far from simple, with an immense amount of preparation and aftercare required for recipients. A
Read More
“Published” is an accolade that many scientists strive for. Showcasing your work and communicating your results to peers feels good, regardless of age. The setting of scientific show and tell is within scientific journals, offering an enduring record of a scientist’s findings and impact on the world (vastly less obtrusive than being sat down and
Read More